Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tazemetostat Expanded Access Program for Adults With Solid Tumors

NCT03874455 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.

NCT NCT03874455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03874455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Lead sponsor
Epizyme, Inc.
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

atrt, chondrosarcoma, desmoplastic small round cell tumor (dsrct), epithelioid malignant peripheral nerve sheath tumor, epithelioid sarcoma (ex-us only), intramedullary spinal cord schwannomatosis, malignant mesothelioma, malignant rhabdoid tumor, malignant rhabdoid tumor of kidney, malignant rhabdoid tumor of ovary, myoepithelial carcinoma, myxoid spindle cell sarcoma, poorly differentiated chordoma, renal cell carcinoma, renal medullary carcinoma, sinonasal carcinoma, small cell carcinoma of the ovary hypercalcemic type, spindle cell sarcoma, synovial sarcoma, thoracic sarcoma